

AF: JNW

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/625,626	
	Filing Date	July 24, 2003	
	First Named Inventor	Stephen P. Adams	
	Art Unit	1626	
	Examiner Name	Janet L. Coppins	
Total Number of Pages in This Submission	5	Attorney Docket Number	14937.0003 D2


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input checked="" type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Receipt Postcard (1)
<div>Remarks</div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm Name			
Signature			
Printed name	Harold H. Fox		
Date	March 10, 2005	Reg. No.	41,498

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:			
Signature			
Typed or printed name		Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application No.	: 10/625,626	Art unit	: 1625
Applicant	: Steven P. Adams et al.	Examiner	: Janet L. Coppins
Filing date	: July 24, 2003		
Title	: CELL ADHESION INHIBITORS		

Mail Stop AF

Customer Service Window
Randolph Building
401 Dulaney Street
Alexandria, VA 22314

REPLY TO OFFICE ACTION MAILED JANUARY 13, 2005

In response to the Office Action mailed January 13, 2005 ("Office Action"), Applicants submit the following remarks.

REMARKS

Applicants thank the Examiner for indicating that claims 1-7, 10 and 11 are allowable. Claims 12-15 stand rejected.

Rejection under 35 U.S.C. § 112, first paragraph

Claims 12-15 have been rejected by the Examiner under 35 U.S.C. § 112, first paragraph, for lack of enablement. Claim 12 is independent, and claims 13-15 depend from it.

The Examiner contends that claims 12-15 are not supported by a specific asserted utility or a well established utility that would enable one skilled in the art to know how to use the claimed invention. See the Office Action at page 2. Specifically, the Examiner contends that because "claim 12 is not directed to a method of treating a disease," the Applicants have failed to set forth a definable utility. See the Office Action at page 2.

Independent claim 12 is directed to a method of preventing, inhibiting or suppressing cell adhesion in a mammal in need thereof. To satisfy enablement under 35 U.S.C. § 112, "All that is necessary is that one skilled in the art be able to practice the *claimed* invention, given the level of knowledge and skill in the art." (emphasis added) MPEP 2164.08; *see e.g. In re Fisher*, 427 F.2d 833, 839, 166 USPQ 18, 24 (CCPA 1970). At the time of filing, one of ordinary skill in the art would have been apprised of the disclosed article, Lobb, R.R. and Hemler, M.E., "The Pathophysiologic Role of $\alpha 4$ Integrins In Vivo," *J. Clin. Invest.*, 94, pp. 1722-29 (1994) ("Lobb"), which indicates that "rapidly accumulating in vivo data... suggest that $\alpha 4$ integrin-